About the job
At Revolution Medicines, we are at the forefront of precision oncology, dedicated to pioneering innovative therapies designed to target the most challenging aspects of RAS-addicted cancers. Our robust R&D pipeline includes RAS(ON) Inhibitors, which aim to inhibit various oncogenic RAS protein variants, and RAS Companion Inhibitors for strategic combination therapies. As an integral member of our passionate team, you will contribute to transforming patient outcomes for those battling cancers linked to mutations in the RAS signaling pathway.
Position Summary:
The Senior Director of HEOR/RWE will play a pivotal role in shaping the strategic direction and execution of HEOR initiatives for all Revolution Medicines assets aimed at addressing non-small cell lung cancer (NSCLC). This position is key in showcasing the value of our products to healthcare decision-makers, ensuring informed choices for patient care. Collaboration with the Medical Affairs team and other cross-functional units will be essential in refining the Integrated Evidence Plan (IEP) and generating robust evidence to support our products' utilization. The ideal candidate will provide strategic insights into the global value of our offerings and have a proven record in evidence generation on a worldwide scale. This role presents a unique opportunity to contribute to the evolution of oncology care by providing compelling evidence that influences treatment paradigms.

